FDA's New Diabetes Drug Warning Includes Meds from J&J, AstraZeneca, Lilly

The U.S. FDA has warned that sodium-glucose cotransporter-2 (SGLT2) inhibitors -- a class of type 2 diabetes drugs -- can lead to ketoacidosis.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news